Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey.
adverse effects
antirheumatic agents
drug-related side effects and adverse reactions
patient-reported outcome measures
rheumatoid arthritis
Journal
The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
accepted:
09
02
2022
pubmed:
3
3
2022
medline:
26
10
2022
entrez:
2
3
2022
Statut:
ppublish
Résumé
To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective. We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Results were summarized to report their frequency, and regression models were used to estimate their associations with RA medication use and overall bother. The 560 patients who completed the survey and reported taking ≥ 1 RA medication (disease-modifying antirheumatic drugs [DMARDs], steroids, nonsteroidal antiinflammatory drugs [NSAIDs]), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1-10 (28%), 11-20 (28%), and > 20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%), or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22, respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles. In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.
Identifiants
pubmed: 35232804
pii: jrheum.210688
doi: 10.3899/jrheum.210688
doi:
Substances chimiques
Prednisone
VB0R961HZT
Antirheumatic Agents
0
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
998-1005Subventions
Organisme : CIHR
ID : FRN 156267
Pays : Canada
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2022 by the Journal of Rheumatology.